Log in


-0.06 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $7.85
50-Day Range
MA: $7.72
52-Week Range
Now: $7.85
Volume8,397 shs
Average Volume9,435 shs
Market Capitalization$8.40 million
P/E RatioN/A
Dividend YieldN/A
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BNTC



Sales & Book Value

Annual Sales$12.52 million
Cash Flow$3.57 per share
Book Value$19.75 per share



Market Cap$8.40 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable
-0.06 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions

How has BENITEC BIOPHAR/S's stock been impacted by COVID-19 (Coronavirus)?

BENITEC BIOPHAR/S's stock was trading at $3.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BNTC shares have increased by 105.0% and is now trading at $7.85.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of BENITEC BIOPHAR/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BENITEC BIOPHAR/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BENITEC BIOPHAR/S

When is BENITEC BIOPHAR/S's next earnings date?

BENITEC BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for BENITEC BIOPHAR/S

What price target have analysts set for BNTC?

1 brokers have issued 1-year target prices for BENITEC BIOPHAR/S's stock. Their forecasts range from $14.00 to $14.00. On average, they expect BENITEC BIOPHAR/S's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 78.3% from the stock's current price.
View analysts' price targets for BENITEC BIOPHAR/S

Has BENITEC BIOPHAR/S been receiving favorable news coverage?

Media headlines about BNTC stock have trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BENITEC BIOPHAR/S earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about BENITEC BIOPHAR/S

Are investors shorting BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S saw a increase in short interest in July. As of July 15th, there was short interest totaling 5,200 shares, an increase of 44.4% from the June 30th total of 3,600 shares. Based on an average daily volume of 33,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the shares of the stock are sold short.
View BENITEC BIOPHAR/S's Current Options Chain

Who are some of BENITEC BIOPHAR/S's key competitors?

What other stocks do shareholders of BENITEC BIOPHAR/S own?

Who are BENITEC BIOPHAR/S's key executives?

BENITEC BIOPHAR/S's management team includes the following people:
  • Dr. Jerel A. Banks, CEO & Exec. Chairman
  • Ms. Georgina Kilfoil, Chief Devel. Officer (Age 50)
  • Ms. Megan Joan Boston, Exec. Director & Head of Operations - Australia
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist


(BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is BENITEC BIOPHAR/S's stock symbol?

BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC."

How do I buy shares of BENITEC BIOPHAR/S?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BENITEC BIOPHAR/S's stock price today?

One share of BNTC stock can currently be purchased for approximately $7.85.

How big of a company is BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S has a market capitalization of $8.40 million and generates $12.52 million in revenue each year.

What is BENITEC BIOPHAR/S's official website?

The official website for BENITEC BIOPHAR/S is www.benitec.com.

How can I contact BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-8692-7222 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.